1. Scrip
  2. >>Business

Torrent’s Entry Into Indian Trade Generics Signals Strategy Shift

US Launches Still Held Back

 
• By Vibha Ravi

Faced with a slowdown in the US from a lack of regulatory approvals, Torrent Pharma is looking at alternate growth strategies. Its entry into the trade generics segment in India, joining other pharma majors, is one to be watched as it marks a strategic shift.

Generic Medicines
Trade Generics In India See An Increase In Interest • Source: Alamy

Torrent Pharmaceuticals Ltd. has joined the league of pharma majors with a trade generics portfolio in India, a move likely triggered by a slow down in the US, its largest overseas market, as well as a consumer segment’s preference for cheaper alternatives to branded generics. 

The current government’s focus on providing economical drugs through “Pradhan Mantri Bhartiya Janaushadhi Kendras”, or public medical retail outlets, has...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Business

BREAKING: Novo Nordisk To Buy MASH Specialist Akero In $5.2bn Deal

 
• By Kevin Grogan

Third deal in FGF21 analog space in the past five months,

Biopharma Financing Veers Toward Optimism, But Cell And Gene Therapies Left Behind

 
• By Mandy Jackson

While there may be the beginnings of a turnaround in biopharma capital markets, gains in the cell and gene therapy space may lag the broader sector recovery, noted speakers at ARM’s Cell and Gene Meeting on the Mesa.

Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal

 
• By Joseph Haas

Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

More from Scrip

Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal

 
• By Joseph Haas

Licensing a BTK inhibitor for progressive MS previously held by Biogen, Zenas says Phase III orelabrutinib can stave off disability related with disease progression.

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

 
• By Alaric DeArment

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.